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ABSTRACT 
Diabetes is an increasing public health problem affecting a breathtaking number of people 
worldwide. The knowledge about modifiable lifestyle factors influencing diabetes risk is 
extensive for type 2 diabetes, but limited for autoimmune forms of diabetes such as type 1 
diabetes. Latent autoimmune diabetes in adults (LADA) is a hybrid form of diabetes with 
characteristics of both type 1 and type 2 diabetes. Diet has an important role in the development 
of type 2 diabetes but its role in autoimmune diabetes is largely unknown. The aim of this thesis 
was to study the risk of LADA in relation to intakes of fish and sweetened beverages, two 
commonly consumed foods hypothesized to play a role in the development of both type 1 and 
type 2 diabetes. 
Analyses were based mainly on ESTRID, a Swedish case-control study with incident cases of 
LADA and type 2 diabetes, and population-based controls. All participants in ESTRID were 
aged ≥ 35 years and LADA was defined by the presence of glutamic acid decarboxylase 
autoantibodies (GADA) and a level of C-peptide indicating remaining insulin secretion. Data 
on intakes of fish and sweetened beverages were available from questionnaires and investigated 
in relation to risk of LADA and type 2 diabetes. One study was based on data from EPIC-
InterAct, a case-cohort study with prospective data from eight European countries. In EPIC-
InterAct, we assessed the interaction of baseline GADA positivity and self-reported dietary fish 
or plasma n-3 PUFA in relation to the risk of adult onset diabetes. 
Based on ESTRID, weekly fatty fish intake was associated with 49% reduced risk of LADA 
(odds ratio [OR] 1.51, 95% confidence interval [CI] 0.30-0.87), whereas no association was 
found for type 2 diabetes (OR 1.01, 95% CI 0.74-1.39). These findings were supported by the 
results from EPIC-InterAct; low fatty fish intake was found to interact with GADA positivity 
on the risk of adult onset diabetes (attributable proportion due to interaction [AP] 0.48, 95% CI 
0.24-0.72), and findings were similar for plasma n-3 PUFA. In ESTRID, sweetened beverage 
intake was positively associated with both LADA and type 2 diabetes. For LADA, the 
increased risk was evident only among carriers of low/intermediate risk HLA genotypes (OR 
per one daily serving 1.32, 95% CI 1.06-1.64). BMI was suggested to only partly mediate the 
associations between sweetened beverages and risk of LADA and type 2 diabetes, indicating 
that there may also be direct effects on glucose homeostasis. 
In conclusion, these results suggest that long-chain n-3 PUFAs from fish may decrease the risk 
of LADA whereas intake of sweetened beverages may increase the risk. Importantly, these 
findings indicate that diet may be a modifiable lifestyle factor influencing the development of 
LADA and hence be a target for preventive strategies.  
  
SAMMANFATTNING PÅ SVENSKA 
Diabetes är en kronisk sjukdom och ett stort folkhälsoproblem. Idag beräknas 1 av 11 vuxna 
vara drabbade av sjukdomen världen över och siffran förväntas öka. Det finns olika former av 
diabetes men gemensamt för alla är att blodsockernivån är för hög, detta på grund av att 
kroppens eget system förlorat förmågan att genom hormonet insulin hålla blodsockret på rätt 
nivå. Personer med diabetes löper även högre risk att drabbas av flera allvarliga sjukdomar 
såsom hjärtinfarkt och stroke. Den vanligaste formen är typ 2-diabetes (vanligaste formen hos 
vuxna), som kännetecknas av att kroppens celler har minskad förmåga att känna av insulinets 
signaler om att ta upp socker från blodet, så kallad insulinresistens. Typ 1-diabetes är en 
autoimmun form av diabetes (vanligaste formen hos barn), vilket innebär att kroppens 
immunförsvar av okänd anledning attackerar och förstör cellerna som ska producera insulin 
vilket leder till insulinbrist. Latent autoimmun diabetes hos vuxna (LADA) har drag av både 
typ 1- och typ 2-diabetes och kännetecknas av både autoimmunitet och insulinresistens. 
Kunskapen om vad som påverkar risken för LADA är mycket begränsad. I den här 
avhandlingen undersöks om konsumtion av fisk och sötade drycker påverkar risken att utveckla 
LADA, något som inte studerats tidigare. Avhandlingen innefattar fyra delstudier, där tre 
baseras på svensk data från ESTRID-studien och en baseras på europeiska data från studien 
EPIC-InterAct. 
I delarbete I undersökte vi sambandet mellan konsumtion av fet fisk och risken att utveckla 
LADA och typ 2-diabetes. Fisk innehåller särskilda omega-3-fettsyror (EPA och DHA) som 
har visats vara fördelaktiga för många olika processer i kroppen. I vissa studier har man sett en 
minskad risk för typ 1-diabetes bland barn med ett högt intag av omega-3-fettsyror. Att äta fisk 
har även föreslagits minska risken för typ 2-diabetes, men studier har visat blandade resultat. I 
ESTRID-studien fann vi att personer som uppgav att de åt fet fisk minst en gång i veckan löpte 
omkring 50% lägre risk för LADA jämfört med dem som åt fet fisk mer sällan. Vi såg inget 
samband mellan fet fisk och typ 2-diabetes. Dessa resultat skulle kunna tyda på att fet fisk kan 
minska risken för LADA genom effekter kopplade till autoimmunitet. 
I delarbete II använde vi data från EPIC-InterAct-studien för att forsätta studera sambandet 
mellan fiskkonsumtion och autoimmun diabetes. Vi fann att personer som vid studiens start 
hade GAD-antikroppar i blodet (påvisar autoimmunitet och är en riskfaktor för diabetes) löpte 
särskilt hög risk om de samtidigt hade lågt intag av fisk. Liknande samband sågs för dem med 
låga nivåer av omega-3-fettsyror (särskilt DHA) i blodet. Dessa resultat ger ytterligare stöd för 
att omega-3-fettsyror från fisk minska risken för diabetes, även hos personer som redan 
utvecklat autoimmunitet. 
I delarbete III undersökte vi sambandet mellan konsumtion av sötade drycker (främst läsk) 
och risken för LADA och typ 2-diabetes baserat på ESTRID-data. Sötade drycker har kopplats 
till ökad risk för typ 2-diabetes i många studier, och ett par studier har även visat en koppling 
till typ 1-diabetes. Läsk innehåller vanligtvis stora mängder socker som dels kan öka risken för 
övervikt men även bidra till insulinresistens. Läsk som innehåller sötningsmedel (light-läsk) 
innehåller inga kalorier men det finns hypoteser kring att light-läsk ändå skulle kunna bidra till 
  
diabetesrisk. Vi fann att hög konsumtion (mer än två glas/dag) av sötade drycker var kopplat 
till en fördubblad risk för både LADA och typ 2-diabetes. För varje extra glas läsk per dag 
ökade risken med 15-20 %. Detta gällde både ”vanlig läsk” och light-läsk, men den ökade 
diabetesrisken kopplad till light-läsk har eventuellt andra förklaringar än att den drycken i sig 
skulle öka risken. Dessa resultat talar för att sötade drycker ökar risken för LADA och att 
LADA delvis har samma riskfaktorer som typ 2-diabetes. 
I delarbete IV ville vi ta reda på hur stor del av sambandet mellan sötade drycker och LADA 
och typ 2-diabetes som förklaras av effekter på BMI, samt om sambandet påverkas av riskgener 
för diabetes. Baserat på ESTRID-studien fann vi att BMI förklarar ungefär hälften av 
sambandet mellan sötade drycker och typ 2-diabetes, och 17% av sambandet för LADA. När 
vi delade upp studiedeltagarna med avseende på genetik, såg vi att den ökade risken för LADA 
kopplad till sötade drycker endast fanns bland personer utan högrisk-varianter av HLA-gener 
(kopplade till autoimmunitet). Däremot verkade inte genen TCF7L2 (riskgen för typ 2-
diabetes) påverka sambanden. Dessa resultat föreslår att konsumtion av sötade drycker ökar 
risken för både LADA och typ 2-diabetes genom mekanismer kopplade till ökad kroppsvikt 
men även att andra mekanismer har betydelse.  
 
Sammanfattningsvis tyder resultaten på att omega-3-fettsyror från fisk minskar risken för 
LADA medan läskkonsumtion är förenat med en ökad risk. Kostfaktorer tycks alltså kunna 
påverka utvecklandet av LADA. Kunskap om riskfaktorer är viktigt eftersom den kan användas 
för att förebygga diabetes. Fler studier behövs dock för att bekräfta de samband som påvisats 
här. 
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1 INTRODUCTION 
Diabetes is a common, chronic disease that manifests when the pancreatic beta cells can no 
longer meet the body’s need for insulin to maintain glucose homeostasis, resulting in 
hyperglycemia. Since there is no cure for diabetes, prevention is key to reduce the number of 
affected individuals. Knowledge about risk factors is necessary for effective disease 
prevention. Lifestyle modifications have been shown to be effective in prevention of type 2 
diabetes [1, 2]. For autoimmune forms of diabetes, such as type 1 diabetes, there is a lack of 
established risk factors suitable as targets for preventive actions [3] and the role of lifestyle is 
largely unknown. For latent autoimmune diabetes in adults (LADA), an autoimmune form of 
diabetes with adult onset, studies are scarce. 
Diet constitutes a major component in primary prevention of type 2 diabetes [2, 4] and several 
dietary risk factors have been identified including sweetened beverages [5]. The role of diet in 
the etiology of autoimmune diabetes is less clear. However, in children, a reduced risk of type 
1 diabetes has been reported in relation to intake of fish, including fish-originated fatty acids 
[6, 7], whereas intake of sweetened beverages has been associated with excess risk [8, 9]. 
Latent autoimmune diabetes in adults (LADA) is a common (9-12% of all adult onset diabetes 
[10, 11]), autoimmune form of diabetes with features of both type 1 and type 2 diabetes. Risk 
factors are largely unknown and the aim of this doctoral thesis was to investigate, for the first 
time, the risk of LADA in relation to dietary fish and sweetened beverage consumption. 
Analyses were based on data from the Swedish ESTRID Study, which is the largest population-
based study of LADA to date, and the European EPIC-InterAct Study, which is a prospective 
study with data on dietary factors, autoantibodies, and incident adult-onset diabetes. The 
overall aim was to contribute to an increased understanding of the etiology of LADA.
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2 BACKGROUND 
2.1 DIABETES 
Diabetes is one of the most common chronic diseases and among the top ten causes of deaths 
worldwide [12]. The prevalence is estimated at 9% in the adult population globally and 7% in 
Sweden [13, 14]. The number of affected individuals has increased tremendously over the past 
decades, from 151 million to 425 million adults with diabetes since the year 2000, and the 
prevalence is projected to continue to rise [13]. The increase is explained by a combination of 
several factors, including changes into a more sedentary lifestyle combined with unhealthy 
dietary habits [15] but also increased life expectancy [16] and improved diabetes survival [14]. 
Diabetes often poses a heavy burden on the individual and also constitutes large healthcare 
costs for society, primarily due to risk of common complications such as cardiovascular 
diseases and problems related to the kidneys (nephropathy), eyes (retinopathy), and the nervous 
system (neuropathy) [15]. Better understanding on how modifiable lifestyle factors, such as 
diet, may impact the development of diabetes is crucial for primary prevention. 
2.1.1 Diagnosis 
Diabetes is characterized by hyperglycemia as a consequence of insulin resistance, insulin 
deficiency, or a combination of the two [17]. The inability to maintain normal blood glucose 
levels may be due to autoimmune destruction of beta cells, or that the insulin production is 
unable to meet the increasing demands due to insulin resistance [18]. Diagnosis is based on 
measurements of fasting plasma glucose, 2-hour plasma glucose after oral glucose tolerance 
test, random plasma glucose together with symptoms of hyperglycemia, or HbA1c [19-21]. 
2.1.2 Subtypes 
Diabetes is a disease with broad manifestation, all characterized by raised blood glucose levels 
but with different pathogenesis. There has traditionally been a division into type 1 diabetes and 
type 2 diabetes, but its heterogeneity has been increasingly recognized and about 25 years ago, 
the term LADA was introduced to describe a subgroup of type 2 diabetes patients with 
autoantibodies [22], similar to type 1 diabetes. Since then the field has been evolving further 
and new diabetes classifications addressing the heterogeneity of type 2 diabetes have recently 
been proposed [23]. In this thesis, I will refer to type 1 diabetes, type 2 diabetes, and LADA as 
the three main subtypes of diabetes. In addition to these, there are a number of monogenic 
diabetes subtypes (e.g. forms of MODY; maturity onset diabetes of the young), gestational 
diabetes, and secondary diabetes which will not be further discussed in this thesis. 
2.1.2.1 Type 1 and type 2 diabetes 
Type 2 diabetes is the most common subtype of diabetes and constitutes about 75-85% of all 
patients [23, 24]. Type 2 diabetes used to be a disease almost exclusively occurring in adults, 
but has become an increasing health concern also among younger age groups [25]. Type 1 
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diabetes is an autoimmune form of diabetes most commonly thought of as affecting children 
and adolescents, but it may also occur in adulthood. 
2.1.2.2 Latent autoimmune diabetes in adults (LADA) 
The term LADA was first presented in 1993 by Tuomi et al [22], although presence of 
autoantibodies in adult patients diagnosed with type 2 diabetes was described already in 1977 
[26] and a latent form of adult type 1 diabetes was described in 1986 [27]. LADA is by many 
considered to be a hybrid form of diabetes because of the presence of autoantibodies similar to 
type 1 diabetes but presenting with a phenotype more similar to type 2 diabetes [18]. LADA 
constitutes about 9-12% of all adult-onset diabetes in Europe [10, 11] and may be the most 
common form of autoimmune diabetes in adults. According to data from the ANDIS (All New 
Diabetics in Scania) study, where newly diagnosed diabetes patients are classified into different 
subtypes based on genetic and clinical features, LADA accounts for about 5% of all incident 
cases (Figure 2.1) [24]. Among all autoimmune diabetes with an adult onset, more than 80% 
may be classified as having LADA [28]. 
There are no unified criteria for LADA classification, but three criteria commonly applied at 
diagnosis are i) adult onset (usually ≥30 or 35 years), ii) autoantibody positivity (predominantly 
GADA), and iii) remaining insulin secretory capacity (absence of insulin therapy 6-12 months 
after diagnosis) [18]. However, the insulin therapy criterion has been questioned as it is open 
to subjectivity [29] and an alternative approach is to use C-peptide levels above a certain cut-
off, as a measure of remaining insulin secretion [23]. The antibody criterion separates LADA 
from type 2 diabetes and the criterion about remaining insulin secretion distinguishes LADA 
from type 1 diabetes. The World Health Organization (WHO) and American Diabetes 
Association however consider LADA as a slowly progressing form of type 1 diabetes [30]. 
 
Figure 2.1. Distribution of different subtypes of diabetes in the ANDIS registry, adapted from the 
ANDIS website [24].  
 
LADA 4.8% (including 1.1% LADA mild)
Type 1 diabetes in adults 0.6%
Type 1 diabetes with relative insulin deficiency 0.7%
Type 1 diabetes with absolute insulin deficiency 6.0%
Type 2 diabetes in youth 2.1%
Type 2 diabetes with relative insulin deficiency 10.7%
Classical type 2 diabetes 72.5%
Secondary diabetes 1.3%
Unclassified 1.3%
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2.1.3 Pathogenesis 
2.1.3.1 Type 2 diabetes 
Type 2 diabetes is characterized by insulin resistance of skeletal muscle, liver, and adipose 
tissue [17], a metabolic condition also related to obesity [31]. Insulin resistance imposes an 
increased insulin demand and hyperglycemia manifests when the capacity of the pancreatic 
beta cells to increase insulin secretion is compromised. Insulin resistance in the liver leads to 
increased gluconeogenesis resulting in fasting hyperglycemia. This, in combination with 
muscle insulin resistance and other impairments in glucose metabolism such as beta cell 
resistance to incretin hormone signaling [32], results in postprandial hyperglycemia [17]. 
Furthermore, the presence of systemic inflammation mediated by pro-inflammatory cytokines 
and macrophage infiltration in adipose tissue is an additional contributor to insulin resistance 
[17]. 
2.1.3.2 Type 1 diabetes 
Type 1 diabetes is a disease where autoimmune processes, mediated by T cells [33], lead to 
destruction of the pancreatic insulin-producing beta cells. This results in insulin deficiency and 
subsequent hyperglycemia. For most patients, the situation rapidly becomes acute and lifelong 
insulin therapy (injections) is needed [34]. Presence of autoantibodies is a hallmark of type 1 
diabetes, but seroconversion, i.e. development of detectable autoantibodies in the blood, may 
have started already earlier in life [35]. There are four major types of autoantibodies related to 
type 1 diabetes; autoantibodies against insulin (IAA), glutamic acid decarboxylase (GADA), a 
tyrosine phosphatase-like protein (islet antigen-2 [IA-2A]), and zink transporter 8 (ZnT8A) 
[33]. Recently, also autoantibodies against tetraspanin 7 (TSPAN7A) has been described [36]. 
Positivity to multiple autoantibodies is associated with a markedly increased risk of progression 
to type 1 diabetes compared to single autoantibody positivity [37]. IAA usually appears as 
primary antibody (the first occurring autoantibody) among patients who become antibody 
positive early in life, whereas GADA is more frequent as primary antibody in children with 
later seroconversion [38]. 
2.1.3.3 LADA 
Similar to type 1 diabetes, LADA is characterized by the presence of autoantibodies. The 
predominantly occurring autoantibody is GADA which is present in 90% of all autoantibody-
positive adult patients [18]. Many LADA patients are positive for a single autoantibody, 
whereas in type 1 diabetes multiple autoantibodies are usually present at time of diagnosis [37]. 
The autoimmune processes are progressing more slowly in LADA than in classic type 1 
diabetes and the patient’s own insulin production is preserved for a longer period of time [11, 
29]. Autoantibodies are prevalent also in the diabetes-free population and positivity confers an 
increased risk of diabetes [39]. 
Despite autoantibody positivity, patients with LADA are phenotypically similar to those with 
type 2 diabetes. In populations where LADA is not routinely diagnosed, about 5-14% of adults 
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diagnosed as type 2 diabetes are autoantibody positive and would fall within the framework of 
LADA [18]. The most important shared feature is insulin resistance, although this may be less 
pronounced than in type 2 diabetes patients [40, 41]. The relative contribution of insulin 
resistance is likely to differ depending on the degree of autoimmunity; those with high GADA 
levels tend to be less insulin resistant whereas those with low GADA levels display a higher 
degree of insulin resistance [28]. The presence of both autoimmunity and insulin resistance is 
likely to have implications for the etiology of LADA and risk factors may be related to either 
one, or both, of these characteristics. 
2.1.3.4 Diabetes treatment 
The aim of diabetes treatment is to target hyperglycemia in order to minimize the risk of 
complications. Common treatments for type 2 diabetes include lifestyle interventions, oral 
glucose-lowering agents and injectable medications [42]. For type 1 diabetes patients, daily 
injections of insulin forms the basis of therapy [43]. For patients with LADA however, there 
are currently no specific treatment guidelines. Hence, patients may not receive the optimal 
treatment, which may lead to adverse effects such as more rapid beta cell loss [44]. 
2.1.4 Genetics 
2.1.4.1 Type 2 diabetes 
More than 400 susceptibility loci have been associated with type 2 diabetes [45], most of them 
related to insulin secretion rather than insulin resistance [46]. The strongest genetic determinant 
of type 2 diabetes is TCF7L2 [47]. TCF7L2 encodes transcription factor 7-like 2 which is a key 
effector in the Wnt signaling pathway and suggested mechanisms for its role in type 2 diabetes 
development include impaired insulin secretion and enhanced rate of hepatic glucose 
production [48]. Another important risk gene is the fat-mass and obesity-associated (FTO) 
gene, for which carriers of common risk variants are predisposed to develop obesity and type 
2 diabetes [49]. Underlying mechanisms are believed to include changes in satiety perception 
and energy intake [50, 51]. Despite the large number of identified type 2 diabetes susceptibility 
genes, they collectively still only explain a small part of the heritability [46]. 
2.1.4.2 Type 1 diabetes 
The strongest genetic determinants for type 1 diabetes risk are located in the human leukocyte 
antigen (HLA) region on chromosome 6. The system covers several genes related to the 
immune system and is highly polymorphic and HLA genotypes are estimated to be responsible 
for about half of the genetic risk in type 1 diabetes [52]. The strongest association with type 1 
diabetes is found with HLA DR and DQ, which encode cell surface receptors involved in 
antigen-presentation for T-lymphocytes. HLA DR and DQ are tightly linked and risk is 
conferred by specific combinations, or haplotypes. The haplotypes most strongly associated 
with type 1 diabetes are DRB1*04:xx-DQA1*03:01-DQB1*03:02 also referred to as DR4-
DQ8, and DRB1*03:01-DQA1*05:01-DQB1*02:01 also referred to as DR3-DQ2. The 
heterozygous DR4-DQ8/DR3-DQ2 genotype confers the highest risk with odds ratio (OR) of 
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16. Some HLA haplotypes are associated with protective effects, such as DRB1*15:01 (DR2)-
DQA1*01:02-DQB1*06:02 [53]. 
In addition, there are more than 50 non-HLA genes associated with type 1 diabetes. Important 
non-HLA polymorphisms include the insulin gene (INS), protein tyrosine phosphatase non-
receptor type 22 gene (PTPN22), interferon-induced with helicase C domain 1 (IFIH1) [54], 
and cytotoxic T-lymphocyte associated protein (CTLA-4) [53]. The risk variant of TCF7L2, 
conferring the strongest genetic risk of type 2 diabetes, is more frequently found among non-
carriers of high risk HLA genotypes compared to risk genotype carriers among childhood type 
1 diabetes patients [55]. 
2.1.4.3 LADA 
Studies conducted to date indicate that LADA shares most of its genetic background with type 
1 diabetes. This was highlighted in the first genome-wide association study (GWAS) of LADA 
published recently [56]. The strongest genetic determinants for LADA are the HLA genes [57] 
and, similar to type 1 diabetes, the haplotypes conferring the strongest risk are DRB1*04-
DQB1*03:02 (DR4-DQ8) and DRB1*03:01-DQB1*02:01 (DR3-DQ2), albeit with attenuated 
effect size [57, 58]. In addition, high risk HLA genotypes seem to correlate with GADA level 
[59]. The protective HLA-DQB1*06:02/X and HLA-DQB1*06:03/X seem to be more frequent 
among individuals with LADA compared to type 1 diabetes [57, 58]. A number of non-HLA 
type 1-related genes have also been associated with LADA, including variants in PTPN22 and 
INS [57]. The LADA GWAS also confirmed a genetic overlap with type 2 diabetes, but less 
clear than for the autoimmune-related genes [56]. An association with the type 2 diabetes risk 
gene TCF7L2 could not be confirmed at the genome-wide significance level, but has been 
demonstrated in several other studies [60] including two based on Swedish data [58, 61]. With 
regard to the FTO gene, one study based on data from the Norwegian HUNT Study have 
reported an association for LADA, especially among patients with low GADA levels [62], but 
replication is needed for verification. Based on the genetic background, autoimmunity seems 
to be the major driving force in the development of LADA. In line with this, family history of 
type 1 diabetes is a stronger risk factor for LADA than family history of type 2 diabetes [63]. 
2.1.5 Environmental and lifestyle risk factors 
2.1.5.1 Type 2 diabetes 
The contribution of environmental and lifestyle factors in the development of type 2 diabetes 
is substantial and much is known when it comes factors affecting risk of disease. Lifestyle plays 
an important role and excess adiposity, indicated by high body mass index (BMI), is the 
strongest single risk factor by its contribution to insulin resistance. In addition, increased 
abdominal fat has been shown to be a risk factor independent of BMI [15]. Other important 
risk factors include low quality diet which will be further discussed below (Section 2.2.1.1), 
but also low physical activity [64], sedentary lifestyle [65], cigarette smoking (in a dose-
dependent manner) [67], air pollution [67], sleep duration [68], and psychological stress [69]. 
All of these risk factors are thought to influence risk of type 2 diabetes through mechanisms 
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contributing to impaired insulin sensitivity. Lifestyle interventions including modifications in 
diet and physical activity have been shown effective for weight loss and subsequent reduction 
in type 2 diabetes risk [2, 70]. 
2.1.5.2 Type 1 diabetes 
Europe has the highest incidence of childhood type 1 diabetes, where Finland is in the top and 
Sweden comes second with an annual incidence of 40 new cases per 100,000 children aged 
<15 years [71]. A dramatic increase in incidence has been seen over the past decades; a 
doubling of childhood cases in Europe during the past 20 years [72]. This increase is unlikely 
to be explained by genetic changes but rather by an increased prevalence of environmental risk 
factors. Such factors could potentially act by triggering autoimmunity or promote the 
progression from islet autoimmunity to type 1 diabetes, or both. 
Established environmental risk factors are lacking despite large efforts. However, exposure to 
enteroviruses is the factor most consistently associated with type 1 diabetes risk [73-75]. Other 
factors that have been proposed to increase the risk are respiratory infections [76], maternal 
age at delivery, high birthweight [77], accelerated weight gain early in life [78], and childhood 
adiposity [54, 79], but also serious life events and psychological stress [80]. Furthermore, there 
has been an increasing interest in the gut microbiota and its potential role in type 1 diabetes 
development [81], and is even discussed as a potential target for preventive interventions [82]. 
Alterations in gut microbiota (e.g. lower diversity) may be induced by several factors including 
diet (further discussed in Section 2.2.1.2), birth delivery mode (Ceasarian section) [83], 
antibiotics use, low exposure to viral infections, or excessive hygiene (’the hygiene 
hypothesis’) [84, 85], which are all candidate factors for modulating type 1 diabetes risk [75]. 
It has proven difficult to replicate findings across studies and so far, attempts to prevent type 1 
diabetes through lifestyle modification has been unsuccessful [3]. 
2.1.5.3 LADA 
Given the hybrid nature of LADA, risk factors may have underlying mechanisms related to 
autoimmunity or/and insulin resistance. At present, there is a paucity of studies on 
environmental and lifestyle risk factors for LADA. One probable reason is that most studies 
with incident cases lack information about antibody status which is required to distinguish 
LADA from type 2 diabetes. Antibodies are not routinely measured in health care. The few 
studies investigating risk of LADA in relation to lifestyle factors conducted to date have all 
been based on data from two population-based studies in Norway and Sweden; the prospective 
HUNT Study [86] and the case-control study ESTRID [28]. Findings from HUNT and ESTRID 
suggest that LADA, despite its autoantibody positivity, may share several risk factors with type 
2 diabetes; increased age, overweight, physical inactivity [87], family history of diabetes [88, 
63], low birthweight [89], heavy smoking [90], sleep disturbances and low psychological well-
being [91], which supports the importance of insulin resistance in the development of LADA. 
Some of these studies also highlight that the group of LADA patients is heterogeneous; for 
some of these factors, the associations vary depending on degree of autoimmunity [63, 90]. 
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2.2 DIETARY RISK FACTORS 
2.2.1 Overview 
2.2.1.1 Type 2 diabetes 
Diet has been shown to play an important role in the development, and hence also for 
preventive actions, of type 2 diabetes [2, 92]. Lower risks are generally seen with adherence to 
a Mediterranean diet which is characterized by high intakes of nuts, vegetables, legumes, fruits, 
fish and seafood, and moderate alcohol intake, and often limited intakes of red and processed 
meat, (high fat) dairy products, and either high olive oil intake or high monounsaturated fatty 
acid (MUFA) to saturated fatty acid (SFA) ratio [93, 94]. Contrary, positive associations have 
been observed for a Western diet which include high consumption of red and processed meat, 
fried products, high fat dairy products, refined grains, and sweets [95]. The beneficial effects 
of the Mediterranean diet have been attributed to cardiovascular improvements and reductions 
in fasting levels of glucose and insulin, insulin resistance, and inflammatory markers [96] 
whereas the Western diet has been related to increases in inflammatory markers [97]. Dietary 
components associated with lower risks are whole grain [5, 98], total dairy products [5, 99] 
which may be attributed to low-fat dairy products and/or yoghurt intake [99] although 
controversies exist [100], fruits [5, 101], vegetables [5] – specially green leafy vegetables [101], 
coffee [102], low to moderate alcohol consumption [103], and fatty fish intake (further 
discussed in Section 2.2.2.4) [104]. Increased risks have been proposed for intakes of 
sweetened beverages (further discussed in Section 2.2.3.3) [5, 105], red and processed meat 
[5], and diets high in glycemic load [106]. 
A role of total protein intake in the development of type 2 diabetes has also been discussed, 
with increased risks in relation to total protein which may be attributed to protein from animal 
sources [107, 108] whereas inverse associations for have been suggested for plant-based 
proteins [109]. A high PUFA:SFA ratio has been associated with lower risk of type 2 diabetes 
and trans fatty acids have been positively associated [110], but more recent findings suggest 
that the potential role of specific fatty acids may also vary by their carbon length; in EPIC-
InterAct, plasma phospholipid even-chained SFAs were positively associated but odd-chained 
SFAs were inversely associated with type 2 diabetes [111]. Furthermore, the degree of 
unsaturation may affect the roles of specific fatty acids; among n-6 PUFAs the direction of 
association with type 2 diabetes was different for fatty acids with two, three, or four double 
bonds [112]. Taken together, a lot is known when it comes to dietary factors and their 
association with type 2 diabetes, but the specific components in foods and the underlying 
mechanisms explaining these associations are not fully elucidated. 
2.2.1.2 Type 1 diabetes 
Several dietary factors have been hypothesized to influence development of islet autoimmunity 
and type 1 diabetes but results have been inconsistent and no associations have been firmly 
established [113]. Dietary factors proposed to increase the risk include cow’s milk [114-117], 
high sugar intake [9], low omega-3 PUFA intake and status [7], low vitamin D intake [118] 
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and 25-hydroxyvitamin D status [119, 120], and intake of nitrate and nitrite [121]. The timing, 
with regard to age but also to cessation of breastfeeding, for infant introduction to solid foods 
or specific foods such as gluten/cereal products [122, 123], fruits [122, 124], and root 
vegetables [124], may be of importance. The notion that risk factors for type 1 diabetes may be 
related to the gut microbiota is highly relevant when it comes to diet since the gut microbiota 
composition is vastly influenced by environmental factors such as diet [125, 126]. In support 
of an important role of gut microbiota, early supplementation of probiotics have been inversely 
associated with islet autoimmunity [127], however probiotic supplementation during the first 
six months in life was not associated with islet autoimmunity and type 1 diabetes [128]. 
Importantly, the vast majority of studies have been carried out in children, or siblings of 
children, and often in those with genetic susceptibility. Studies in adults, with and without 
genetic risk, are lacking. 
2.2.1.3 LADA 
To hypothesize that diet may influence the risk of LADA is not far-fetched, given the large 
number of dietary factors studied in relation to type 1 and type 2 diabetes discussed above. 
Despite this potential, the number of studies are few. In fact, by the start of this thesis project, 
only alcohol consumption had been assessed in relation to LADA risk; based on data from 
ESTRID and HUNT studies, an inverse association with moderate alcohol intake was found 
but suggestively only among patients with mild autoimmunity (low GADA levels) [129, 130], 
which is similar to observations in type 2 diabetes [103]. In addition, we later found coffee 
consumption to be positively associated with LADA but only in those with high GADA levels 
[131]. Interestingly, this contrasts previous findings in type 2 diabetes [102]. Along those lines, 
we recently showed that heavy coffee consumption may interact with high risk HLA genotypes 
on the risk of LADA [132], suggesting potential mechanisms related to autoimmunity. 
This thesis project focuses on the role of dietary fish and sweetened beverage consumption in 
development of LADA. There are hypotheses relating dietary fish intake and related nutrients 
as well as sweetened beverage consumption to risk of both type 1 and type 2 diabetes (presented 
in the next section), but their association with LADA has not been previously investigated. This 
thesis is based primarily on data from the ESTRID Study since the dietary information in 
HUNT is limited to indicator questions on key dietary factors [133]. One of the included studies 
is however based on data from the prospective EPIC-InterAct Study [134]. Here, it is not 
possible to study incident LADA (requires known antibody status at diagnosis) but instead, 
GADA measured at baseline (i.e. before diabetes onset) could be explored as a risk factor 
including its potential interaction with other risk factors such as diet. A schematic summary of 
the background for this thesis work is presented in Figure 2.2 (page 14). 
2.2.2 Fish consumption 
Dietary fish is rich in several important nutrients and considered part of a healthy diet. The 
dietary guidelines in Sweden recommend consumption of fish and shellfish two to three times 
a week, and to alter between types of fish consumed (www.slv.se). Fish is the most important 
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dietary source of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are 
long-chain polyunsaturated omega-3 fatty acids (n-3 PUFA), and one of the most important 
sources of vitamin D. However, dietary fish is also a source of environmental contaminants 
that may have adverse health effects [135, 136]. 
2.2.2.1 Long-chain omega-3 fatty acids (n-3 PUFA) 
EPA and DHA are synthesized endogenously by elongation and desaturation of α-linoleic acid 
(ALA), an essential fatty acid with shorter carbon chain found in plant-based foods. However, 
this interconversion is very limited and may be as low as <1% for DHA [137]. For this reason, 
these fatty acids must be acquired through foods (or as dietary supplements). EPA and DHA 
have anti-inflammatory properties, which may be of relevance in diabetes prevention as both 
type 1 and type 2 diabetes have been described as having an inflammatory component [138, 
139], and immunomodulatory properties through altered maturation and differentiation of  T 
cells [140]. Also beneficial effects on insulin resistance has been demonstrated in animals [141] 
but findings are less consistent in humans [142]. The amount of n-3 PUFA is larger in fatty fish 
such as salmon and herring, and lower in lean fish such as cod and pollock. As an objective 
biomarker for dietary fish intake, measurements of EPA and DHA in various biological 
compartments is commonly used [143]. 
2.2.2.2 Vitamin D 
Vitamin D is synthesized in the skin by sun exposure (ultraviolet-B radiation). The possibility 
to reach adequate vitamin D levels decreases with increasing latitude. In Sweden and other 
countries at a latitude above 40°, vitamin D synthesis cannot occur during the dark months of 
the year [144] and therefore it has to be acquired through food (as vitamin D3 or D2). After 
hydroxylation in the liver, into 25-hydroxyvitamin D [25(OH)D3], and in the kidney, the 
biologically active form 1,25(OH)2D3 is reached [145]. Dietary fish is one of the major dietary 
sources of naturally occurring vitamin D. Almost all immune cells have vitamin D receptors 
(VDR), which implies that vitamin D has an important role in immune function. Several 
diabetes-related health benefits have been proposed to be linked to vitamin D, including anti-
inflammatory effects and preventive effects on autoimmunity through mechanisms such as 
reduced stimulation of T cells, but there may also be direct effects on pancreatic beta cells and 
insulin secretion [145]. 
2.2.2.3 Environmental contaminants 
Dietary fish is also our primary source of exposure to persistent organic pollutants (POPs), 
especially polychlorinated biphenyls (PCBs) [135]. POPs have been shown to induce insulin 
resistance in rodents [146], and a positive association has been suggested with type 2 diabetes 
in humans [147]. Another contaminant present in fish in methyl mercury [136], which has been 
suggested to induce beta cell dysfunction [148]. 
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2.2.2.4 Dietary fish consumption and risk of diabetes 
The risk of type 2 diabetes in relation to dietary fish intake remains inconclusive and there are 
indications of regional differences with associations being positive for studies in North 
America, inverse for Asian and Australian studies, and no overall association in studies from 
Europe [149]. Differences in preparation methods or level of contamination in different species 
may partly explain the observed discrepancies [150]. Analysis of fish subtypes have suggested 
an inverse association for fatty fish based on data from European and Asian populations [104]. 
Moreover, serum levels of n-3 PUFA have been associated with lower risk of type 2 diabetes, 
with the strongest association seen for DHA [151]. 
Protective effects of fish intake and n-3 PUFA on islet autoimmunity or/and type 1 diabetes 
have been suggested as cod liver oil supplementation during first year of life was shown to be 
associated with decreased risk of developing type 1 diabetes [6]. Similarly, an American study 
reported reduced risk of islet autoimmunity in relation to total intake of n-3 PUFA with a 
similar tendency for marine-derived n-3 PUFA [7], but no association with progression to type 
1 diabetes [152]. Moreover, a Finnish study found no association of serum EPA and DHA on 
islet autoimmunity [153]. Inverse associations for vitamin D and development of islet 
autoimmunity or/and type 1 diabetes are reported by some studies [118-120] but not others 
[154, 155]. Studies on dietary fish intake and objectively measured n-3 PUFA exposure are 
lacking with regard to autoimmune diabetes with an adult onset. 
2.2.3 Sweetened beverage consumption 
2.2.3.1 Sugar-sweetened beverages 
The consumption of sugar-sweetened beverages has been increasing over the past decades 
[156]. Sugar-sweetened beverages contribute energy in the form of rapidly absorbed sugars but 
have low nutritional value. Consumption is associated with weight gain [158] with one 
explanation being that liquid calories are less likely to be fully compensated for in subsequent 
meals when compared to solid foods, possibly due to reduced satiety signaling [158, 159]. 
Apart from increased adiposity, there may also be independent increase in insulin resistance 
[160, 161], possibly through adverse effects of fructose-induced hepatic lipid synthesis [162, 
163]. Furthermore, high sugar intake has been associated with increased inflammation [164] 
and demonstrated to induce beta cell apoptosis through oxidative stress [165] or beta cell 
overload [166]. Carbon-13 has been suggested as a biomarker for sugar-sweetened beverage 
intake but is not frequently used [167]. 
2.2.3.2 Artificially sweetened beverages 
As an alternative to sugar, some beverages instead contain artificial (nonnutritive) sweeteners 
such as aspartame and acesulfame K. Stevia is another nonnutritive sweetener which is plant-
based. In this text, all nonnutritive sweeteners will be referred to as artificial. Artificial 
sweeteners contribute with no or very few calories and that way do not directly add to the 
glycemic load or total daily energy intake. However, artificially sweetened beverages have 
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been suggested to enhance appetite due to distorted satiety signaling [168] and cause alterations 
in gut microbiota with subsequent deterioration in glucose tolerance [169, 170]. 
2.2.3.3 Sweetened beverage consumption and risk of diabetes 
The large body of evidence linking sugar-sweetened beverage intake to type 2 diabetes is 
convincing [5]. The association may partly be mediated by BMI, but there also seems to be an 
association independent of adiposity [105]. The role of artificially sweetened beverages in the 
development of type 2 diabetes is controversial; a positive association has been suggested [105] 
but may be explained by BMI or confounding by other dietary or lifestyle factors [171-173]. 
The role of sweetened beverages in the development of autoimmune diabetes is less clear. 
Positive associations with sugar-sweetened beverage intake have been reported in two studies 
from North America [8, 9], but no association was seen in a Swedish study [175]. One study 
investigated islet autoimmunity and type 1 diabetes in relation to artificially sweetened 
beverages and found no indication of an association [9]. 
2.2.3.4 The potential influence of genes 
Only one previous study has addressed the potential interaction between intake of sweetened 
beverage and genetic susceptibility on the risk of type 2 diabetes, which was done by means of 
a genetic risk score, but they found no evidence of interaction [175]. Gene-environment studies 
of individual genes are complex due to very modest effects on type 2 diabetes risk. Still, a 
positive association with TCF7L2 (rs12255372) has been indicated to vary across levels of 
glycemic load [176]. The FTO gene has been demonstrated to influence nutrient intake 
preferences [177] and a lower intake of sugar-sweetened beverages, but not artificially 
sweetened, was reported among risk genotype carriers (of rs9939609) compared to those 
without the risk genotype [178]. Furthermore, FTO may interact with dietary intake as a study 
demonstrated that the risk variant was positively associated with type 2 diabetes only in 
combination with low adherence to a Mediterranean diet, but not among risk genotype carriers 
with high adherence (where one score is given for low intake of sugar-sweetened beverages) 
[179]. With regard to type 1 diabetes, one of the North American studies mentioned above 
found a positive association with sweetened beverages only among carriers of a high risk HLA 
genotype who had already developed islet autoimmunity [9]. Whether diabetes-related 
genotypes have a role in a potential association between sweetened beverages and LADA 
remains to be explored. 
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3 AIMS 
The overall aim with this thesis was to investigate consumption of fatty fish and sweetened 
beverages on the development of LADA, and compare to that of type 2 diabetes. 
 
The specific aims were: 
i. to study the risk of LADA and type 1 diabetes in relation to fatty fish consumption and 
dietary supplementation of fish oil and vitamin D (Paper I) 
 
ii. to study the potential role of n-3 PUFA, by measures of dietary fish intake and plasma 
n-3 PUFA, on the progression from islet autoimmunity to diabetes onset in adults 
(Paper II) 
 
iii. to study the risk of LADA and type 2 diabetes in relation to sweetened beverage 
consumption, including separate analysis of sugar-sweetened and artificially sweetened 
beverages (Paper III) 
 
iv. to study whether risk genes for diabetes modify the associations between sweetened 
beverage consumption and risk of LADA and type 2 diabetes, and estimate the 
proportion mediated by BMI (Paper IV) 
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4 SUBJECTS AND METHODS 
4.1 THE ESTRID STUDY (PAPER I, II, IV) 
The ESTRID Study (Epidemiological Study of Risk Factors for LADA and Type 2 Diabetes; 
https://ki.se/imm/estrid) was initiated in 2010 with the overall aim to enable investigations of 
lifestyle risk factors for LADA, including their underlying mechanisms and interaction with 
genetic factors. Such studies were at the time scarce and could in fact be counted on the fingers 
of one hand, all based on the same cohort from Norway, the HUNT Study (The Nord-Trøndelag 
Health Study) [86]. 
4.1.1 Study design 
ESTRID is a Swedish case-control study with incident cases of LADA and type 2 diabetes 
recruited from two diabetes registries; ANDIS (All New Diabetics in Scania; 
http://andis.ludc.med.lu.se) and its sister-study ANDiU (All New Diabetics in Uppsala; 
http://www.andiu.se, recruitment since 2012). The aim of the registries is to include all new 
diabetes cases diagnosed in the regular health care system within the counties of Scania 
(ANDIS) and Uppsala (ANDiU) and classify them based on clinical and genetic characteristics. 
All incident cases of LADA and a random sample of type 2 diabetes cases (four per one LADA 
case) aged ≥ 35 years are invited to participate in ESTRID. Controls without diabetes aged ≥ 
35 years are recruited as a random sample (six per one LADA case) from the Swedish 
Population Register, matched to the cases by county and calendar time (i.e. date of 
participation). ESTRID is an ongoing study which to date includes 584 cases of LADA, 2,033 
cases of type 2 diabetes, and 2,349 controls.  
4.1.2 Study population 
The ESTRID dataset is updated annually. Analyses in Paper I were based on cases and controls 
recruited between September 2010 and July 2013 (only cases who responded to the 
questionnaire within six months of diagnosis to minimize influence of recall bias) including 89 
cases of LADA, 462 cases of type 2 diabetes, and 1,007 controls. Paper III was based on cases 
and controls recruited between September 2010 and July 2015, including 357 cases of LADA, 
1,136 cases of type 2 diabetes, and 1,371 controls with complete information on exposure and 
main covariates. Paper IV, in which we explored gene*environment interaction, was based on 
386 LADA cases and 1,253 type 2 diabetes cases recruited between September 2010 and July 
2017, together with 1,545 controls recruited between 2005 and 2014 within the EIRA Study 
(described in Section 4.1.6.2). The reason for this procedure was that controls within ESTRID 
contribute questionnaire data but no blood samples. 
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Figure 4.1. Schematic of the ESTRID study. 
4.1.3 Clinical information 
Fasting blood samples were collected at time of registration in ANDIS and ANDIU. 
Quantification of GADA was done with an enzyme-linked immunosorbent assay (ELISA), 
where values above 250 IU/ml were censored at 250. Autoantibody positivity was defined as 
≥ 10 IU/ml. Sensitivity was 84% and specificity was 98% at a cut-off level of 10.7 IU/ml [180]. 
C-peptide concentration was measured using Cobas e601 analyzer (Roche Diagnostics, 
Mannheim, Germany) or IMMULITE 2000 (Siemens Healthcare Diagnostics Product Ldt., 
Llanberies, UK). Homeostatic model assessment for insulin resistance (HOMA-IR) and beta 
cell function (HOMA-B) was calculated based on values for fasting blood glucose and C-
peptide in the HOMA2 calculator [181]. 
4.1.4 Classification of diabetes 
Classification of diabetes subtype was based on age at diagnosis, GADA, and C-peptide. 
LADA was defined as age ≥ 35 years, GADA ≥ 10 IU/ml (i.e. autoantibody positivity), and C-
peptide ≥ 0.2 nmol/L (IMMULITE) or ≥ 0.3 nmol/L (Cobas e 601). Similarly, type 2 diabetes 
patients were aged ≥ 35 years, but had GADA < 10 IU/mL (i.e. negative for autoantibodies), 
and C-peptide ≥ 0.60 nmol/L (IMMULITE) or ≥ 0.72 nmol/L (Cobas e 601). In Paper I, which 
was one of the first publications based on ESTRID, we used a cut-off of 20 IU/ml instead of 
10 IU/ml for GADA (classified as ‘LADA mild’ in the ANDIS registry). In all later 
publications based on ESTRID, we instead used the cut-off of 10 IU/ml and addressed the 
heterogeneity of LADA by stratifying the patients by median GADA level. 
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4.1.5 Questionnaire data 
All participants fill out a self-administered questionnaire with a 
wide range of questions including education, height, weight, 
physical activity, smoking, and diet. The cases were specifically 
instructed to report their habits as they had been prior to diagnosis.  
4.1.5.1 Dietary intake estimations 
Dietary habits were assessed by means of a validated [182-184] 
semi-quantitative food frequency questionnaire (FFQ) including 
132 food items intended to cover all parts of the person’s diet. For 
commonly consumed foods and beverages such as coffee, dairy, 
and bread, participants were asked to report the number of predefined servings per day or per 
week. For other food items, the participants were asked to choose from eight predefined 
frequency categories ranging from never to three times per day or more, to indicate intake as 
the average over the past year. Diabetes patients were instructed to report their diet as it had 
been the year preceding diagnosis. Reported intake frequencies were converted to servings per 
day by taking the midpoint of the marked frequency category and used together with age- and 
sex-specific portion sizes to estimate daily intake in grams. Based on these daily intakes, 
estimations of nutrients and total energy intake were calculated by food composition values 
from the Swedish National Food Agency database. Each item in the FFQ represent several 
specific foods, and the relative contribution of each specific food was determined by 
distribution of consumption in the population according to national surveys. Nutrient intakes 
were energy-adjusted according to the residual method [185]. 
For Paper I, the above mentioned data from nutrient calculations were not available. The EPA 
and DHA intake was instead estimated based on EPA and DHA content in the most commonly 
consumed types of fish and shellfish, with nutrient data from the Swedish National Food 
Agency Database. 
4.1.5.2 Fish consumption 
The ESTRID FFQ contains eleven items concerning seafood intake, of which four were 
regarded as fatty fish (herring/Baltic herring/mackerel, salmon, sardines, smoked fish), four 
about lean fish (cod/pollock/plaice/blue hake, tuna, pike/pike perch/perch, fish fingers), and the 
remaining three about other unspecified fish, shellfish, and roe (Figure 4.2). 
4.1.5.3 Dietary supplements 
The questionnaire also asked various dietary supplements. Participants were asked to report if 
each of the stated dietary supplements had ever been consumed (yes/no) and if yes, to specify 
the time period (in years), and to indicate current use. There was one question specifically 
asking about fish oil and one about vitamin D. There were also an open-ended question and the 
respondents reporting any supplement that would without doubt contain fish oil was considered 
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exposed. In addition, there was a question on multivitamin use but this was not considered in 
the analysis of vitamin D. 
 
Figure 4.2. ESTRID FFQ questions about dietary fish intake: “How often do you on average consume 
the following? Mark only one alternative on each row.” 
 
4.1.5.4 Sweetened beverage consumption 
Sweetened beverage consumption were covered by four question in the FFQ of the ESTRID 
questionnaire; two about sugar-sweetened and two about artificially sweetened (Figure 4.3). 
These were part of the section where the respondent was asked to report the number of 200 ml 
glasses consumed per day or per week. In the EIRA questionnaire, sweetened beverages were 
covered by one only question. For this reason, it was not possible to analyze sugar-sweetened 
and artificially sweetened beverages separately in Paper IV. 
 
Figure 4.3. ESTRID FFQ questions about sweetened beverage consumption: “How much do you drink 
of the following? 1 glass = 200 ml” 
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4.1.6 Genetic information 
4.1.6.1 Cases 
Genotyping was performed at the Clinical Research Center in Malmö, Sweden, using iPlex 
Gold Technology (Sequenom, San Diego, CA, USA). Imputation for missing genotypes were 
done on a subset using Infinium CoreExome v1.1 (Illumina, San Diego, CA,USA), which was 
based on the Haplotype Reference Consortium (http://www.haplotype-reference-
consortium.org/; version r1.1 2016) reference panel. Genotyping for HLA was based on three 
SNPs within the major histocompatibility complex (MHC) class II gene region; rs3104413, 
rs2854275, and rs9273363, combined to indicate HLA genotypes or haplotypes according to 
previously described methodology with an accuracy of 99.3% [186]. 
4.1.6.2 Genetic controls 
For the genetic analyses in Paper IV, we used data for diabetes-free controls collected within 
the Swedish EIRA (Epidemiological Investigation of Rheumatoid Arthritis; 
http://www.eirasweden.se) Study. The EIRA study design is very similar to that of ESTRID, 
including the recruitment of randomly selected population-based controls. Controls included 
in the analysis were aged 35 years or older, adhering to the age criteria in ESTRID. SNP data 
for HLA genotyping (rs3104413, rs2854275, rs9273363) was generated from an Infinium 
Illumina 300K immunochip custom array (Illumina, San Diego, CA, USA). Genotypes of 
TCF7L2 rs7903146 and FTO rs9939609 were based on GWAS data derived from an Illumina 
Global Screening array. 
 
4.2 THE EPIC-INTERACT STUDY (PAPER II) 
4.2.1 Study design 
The EPIC-InterAct Project started in 2006 with the overall aim to elucidate the role of diet and 
physical activity, and their interaction with genes, on the risk of type 2 diabetes [134]. InterAct 
is a nested-case cohort consisting of data from eight European countries within the already 
existing EPIC (European Prospective Investigation into Cancer and Nutrition) Study [187], in 
which a total of 340,234 participants were followed for 3.99 million person-years between 1991 
and 2007 (median follow-up 10.9 years). During this time, 12,403 individuals were diagnosed 
with type 2 diabetes. These individuals, together with a subcohort of 16,154 individuals free of 
diabetes at baseline, forms the InterAct case-cohort (Figure 4.4). After exclusions due to 
missing information on covariates, the analyses in Paper II were based on 11,247 diabetes cases 
and 14,981 subcohort participants (including 693 of the cases). 
4.2.2 Blood samples 
Blood samples for all participants were drawn at baseline, i.e. at time of inclusion in EPIC and 
analyzed for autoantibodies against the 65kD isoform of glutamic acid decarboxylase (GADA; 
but referred to as GAD65 antibodies in Paper II) using a radioligand binding assay [188, 189]. 
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Units (U) were expressed relative to the WHO standard [190]. The cut-off for GADA positivity 
was set at ≥ 65 U/ml, determined through a competition assay using recombinant human 
GAD65 (Diamyd Medical, Sweden), as previously described [191]. This corresponds to 
sensitivity of 85% and specificity of 99% [192]. 
The samples were also analyzed for plasma phospholipid fatty acids through solid phase 
extraction followed by hydrolysis and methylation into fatty acid methyl esters which were 
subsequently separated by gas chromatography [193]. Commercial standards were used as 
comparison and the different fatty acids were identified through their retention time and finally 
expressed in mol%, which represents the percentage of total phospholipid fatty acids. 
 
Figure 4.4. Schematic of the EPIC-InterAct case-cohort study design. 
 
4.2.3 Ascertainment of diabetes 
All incident cases of diabetes classified as type 2 occurring during the follow-up period were 
ascertained and verified through a minimum of two out of the following potential sources: self-
report, primary-care registers, secondary-care registers, use of diabetic medication, hospital 
admissions and mortality data. In Denmark and Sweden, all cases were identified through 
linkage to local and national registers for diabetes and prescribed drug registers, for which no 
further verification was considered to be needed. Prevalent cases of diabetes at baseline were 
identified via self-report, doctor’s diagnosis, or use of diabetic medication, and excluded from 
the study. All cases were diagnosed with type 2 diabetes and since no antibody measurements 
were taken at diagnosis, we are unable to distinguish LADA. These cases will for the remainder 
of this text be referred to as ‘diabetes’. 
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4.2.4 Questionnaire data 
Information on education, occupation, and lifestyle including physical activity and smoking 
status was collected for all participants at baseline in a standardized manner across study 
centers. Habitual diet was assessed through self-administered or interviewer-administered 
questionnaires. Development and validation of the dietary questionnaires were performed 
within each country [194, 195]. The dietary intake data was standardized with regard to food 
items and individual nutrients through the use of the EPIC Nutrient Database [196]. 
4.2.4.1 Fish consumption 
Information on dietary fish intake among the EPIC-InterAct participants was divided into fatty 
fish, lean fish, total fish intake (which is the sum of fatty and lean fish), shellfish, and combined 
fish and shellfish intake (also including “other” types of fish such as fish products/fish in 
crumbs, and nonspecific or combined fish). In Paper II, analyses were based on information on 
total fish intake, fatty fish intake, and lean fish intake. 
 
4.3 STATISTICAL ANALYSIS 
4.3.1 The ESTRID Study (Paper I, III, IV) 
In Paper I, III, and IV, conditional logistic regression was used to estimate odds ratios (OR) 
and 95% confidence intervals (CI) of LADA and type 2 diabetes in relation to the exposure of 
interest. Since the cases are incident and the controls are sampled from the population at risk, 
i.e. they are representative of the source population and eligible to become a case, this is also 
called incidence-density sampling. As an implication, the odds ratio may be interpreted as the 
incidence rate ratio or relative risk [197]. In Paper IV, controls from the EIRA Study was used 
and post-matched to the ESTRID cases by age (in 5-year strata) and sex, due to an over-
representation of women in EIRA (as a consequence of the controls originally being matched 
to cases of rheumatoid arthritis; a disease predominantly affecting women). 
In Paper IV, we used causal mediation methodology [198] to estimate the natural direct effect 
and natural indirect effect of high sweetened beverage consumption, and proportion of the 
association between high intake and risk of diabetes that is mediated by BMI. In order for a 
causal interpretation of the effect estimates to be made, there are four assumptions that need to 
be met, namely that there should be no unmeasured confounding between 1) exposure and 
outcome, 2) mediator and outcome, and 3) exposure and mediator, and also 4) there should be 
no mediator – outcome confounder that is affected by the exposure [198]. 
In Paper IV, we also investigated the potential effect modification by genotypes of HLA, 
TCF7L2 rs7903146, and FTO rs9939609 on the association between sweetened beverage 
intake and diabetes. We did so by stratifying the analyses on genotype to obtain OR per 1 daily 
serving increment in intake specific for each genotype. The genotypes were categorized into 
high risk (high risk HLA; ≥ 1 risk allele [T] for rs7903146; ≥ 1 risk allele [A] for rs9939609) 
or low risk (low/intermediate risk HLA; CC in rs7903146; TT in rs9939609). We also assessed 
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the presence of interaction defined as departure from additivity of effects by estimating the 
attributable proportion (AP) due to interaction for the combined effect of high sweetened 
beverage intake (> 2 servings per day) and high risk genotype, compared with non-risk 
genotype carriers with lower intakes (≤ 2 servings per day). AP was based the following 
formula [199]: 
𝑅𝑅11 − 𝑅𝑅10 − 𝑅𝑅01 + 1
𝑅𝑅11
 
where RR denotes the relative risk, but in this study it is replaced by OR because of the case-
control design with binary outcome measure. OR11 represents the doubly exposed, i.e. to both 
high sweetened beverage intake and high risk genotype, and OR10 and OR01 are those exposed 
to one of the factors but not the other. AP > 0 indicates positive interaction, which is considered 
significant when the confidence interval does not include 0. 
4.3.2 The EPIC-InterAct Study (Paper II) 
In Paper IV, Cox proportional hazards regression models were used in the main analyses due 
to the prospective nature of the data. The models were Prentice-weighted as a way to account 
for the over-representation of cases following the case-cohort design [200]. Hazard ratios (HR) 
and 95% CI of incident diabetes in relation to baseline GADA status, plasma levels of n-3 
PUFAs, or dietary fish intake, and for mutually exclusive combinations of antibody status and 
n-3 PUFA/fish were estimated. Age was used as the underlying timescale, and person-years of 
follow-up were calculated from baseline (time of participation) until diabetes diagnosis, death, 
or December 31 2007, whichever occurred first. All models were conditioned on study center 
to handle potential differences between centers or countries. 
The main focus of Paper IV was the interaction analysis in which we wanted to investigate the 
risk of diabetes in relation to the combination of antibody positivity and low dietary fish intake 
or plasma levels of n-3 PUFA. Interaction was defined as departure from additivity and 
expressed as attributable proportion due to interaction (AP). Calculations were based on the 
same formula as presented above, but with HR replacing RR. In these analyses, the double 
exposed (HR11) were those with GADA positivity (or high GADA level) and low 
dietaryfish/plasma n-3 PUFA level. Antibody negativity and high fish/n-3 PUFA was used as 
reference, as the combination representing the lowest risk should be used as reference [201]. 
AP with 95% CI was estimated using the freely available EpiNET tool [202]. 
 
4.4 ETHICAL CONSIDERATIONS 
All participants in ESTRID, EIRA, and EPIC-InterAct provided informed consent. Ethical 
approval for ESTRID, including the addition of EIRA controls, were obtained from the Ethics 
committee at Karolinska Institutet, Stockholm, Sweden. EPIC-InterAct was approved by the 
IARC Institutional Review Board Committee and local approvals were obtained in each 
country.  
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5 RESULTS 
5.1 CHARACTERISTICS OF STUDY PARTICIPANTS 
In ESTRID, individuals with LADA were younger and leaner at diagnosis, had worse beta cell 
function but better insulin sensitivity compared to individuals with type 2 diabetes (Table 5.1). 
Furthermore, high risk HLA genotypes were more frequent in LADA than in type 2 diabetes 
but no difference was seen with respect to risk genotypes of TCF7L2 and FTO. Median time 
since diagnosis was 6.7 months for LADA and 5.1 months for type 2 diabetes. Characteristics 
of study participants in EPIC-InterAct are presented in the manuscript. 
5.2 PAPER I: FATTY FISH CONSUMPTION AND LADA 
Weekly intake of fatty fish was associated with a reduced risk of LADA (OR 0.51, 95% CI 
0.30-0.87) compared to less frequent consumption (Figure 5.1) whereas no association was 
found for type 2 diabetes (OR 1.01, 95% CI 0.74-1.39). Estimations of total EPA and DHA 
intake from seafood sources supported the associations observed for fatty fish. In addition we 
investigated the risk of LADA in relation to dietary supplementation (ever vs. never use) of 
fish oil and vitamin D. These were hampered by very small numbers but the ORs, although 
with wide confidence intervals, were compatible with a reduced risk of LADA in supplement 
users (Figure 5.1).  
Figure 5.1. OR of LADA and type 2 diabetes in relation to fatty fish consumption and dietary 
supplementation of fish oil and vitamin D. The models were adjusted for age, sex, education, smoking, 
physical activity, family history of diabetes, and intakes of alcohol, red meat, fruit and vegetables. 
 
 26 
Table 5.1. Characteristics of patients with LADA or type 2 diabetes, and diabetes-free control subjects included in the ESTRID dataset used for the latest paper included 
in this thesis (Paper IV). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristic Controls LADA Type 2 diabetes pa Genetic controlsb 
No. of individuals 1,790 386 1,253  1,545 
Age (years), mean (SD) 59 (14) 59 (12) 63 (10) <0.0001 58 (10) 
Women, % 52 47 40 0.0064 74 
BMI (kg/m2), mean (SD) 25.9 (4.2) 27.9 (5.3) 31.1 (5.3) <0.0001 25.4 (4.1) 
Overweight (BMI ≥ 25), % 54 70 93 <0.0001 47 
Obese (BMI ≥ 30), % 15 31 51 <0.0001 12 
With family history of diabetes, % 25 42 50 0.0046 - 
High risk HLA genotype, % - 61 31 <0.0001 32 
≥1 risk allele TCF7L2 rs7903146, % - 52 53 0.8225 46 
≥1 risk allele FTO rs9939609, % - 66 68 0.5561 64 
GADA (IU/ml), median (IQR) - 240 (29-250)c -  - 
C-peptide (nmol/l ), mean (SD) - 0.80 (0.52) 1.35 (0.59) <0.0001 - 
HOMA-IR, median (IQR) - 2.7 (1.8-4.4) 3.6 (2.7-4.8) 0.0014 - 
HOMA-B, median (IQR) - 33 (13-65) 68 (42-94) <0.0001 - 
a p for the comparison between LADA and type 2 diabetes. 
b Genetic controls collected within the EIRA Study. 
c High values are censored at 250 IU/ml. 
  27 
5.3 PAPER II: GADA, FISH/N-3 PUFA, AND DIABETES 
In EPIC-InterAct, GADA positivity vs. negativity at baseline conferred a nearly 2-fold 
increased risk of diabetes (HR 1.81, 95% CI 1.49-2.20), which was even more pronounced in 
those with high GADA levels defined as ≥ 167.5 U/ml (HR 2.93, 95% CI 2.27-3.79). Neither 
total fish intake nor plasma n-3 PUFA was associated with the risk of diabetes (highest vs. 
lowest tertile: HR 1.03, 95% CI 0.93-1.15, and HR 1.01, 95% CI 0.93-1.11, respectively). 
Despite the lack of overall association, consumption of both total fish and fatty fish was found 
to interact with GADA status in relation to the risk of diabetes; HR for positivity combined 
with low intake was 2.52 (95% CI 1.76-3.63) and 2.48 (95% CI 1.79-3.45), respectively. 
Estimations of AP indicated that 44-48% (95% CI 16-72%) of the doubly exposed cases could 
be attributed to the interaction between the two exposures. The highest risk of diabetes was 
seen in individuals with high GADA levels combined with low levels of total n-3 PUFA (HR 
4.26, 95% CI 2.70-6.72, with AP 0.46, 95% CI 0.12-0.80), and plasma DHA (HR 4.30, 95% 
CI 2.86-6.47, with AP 0.43, 95% CI 0.08-0.77) (Figure 5.2). 
Figure 5.2. Multivariable adjusted HR (95% CI) of adult onset diabetes by mutually exclusive 
combinations of GADA status and plasma levels of a) n-3 PUFA and b) DHA measured at baseline in 
the EPIC-InterAct Study. The models were adjusted for age (as underlying time-scale, center, sex, 
education, smoking, physical activity, BMI, alcohol, fruit and vegetable intake. 
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5.4 PAPER III: SWEETENED BEVERAGE CONSUMTION AND LADA 
In Paper III we investigated the association between sweetened beverage intake and LADA or 
type 2 diabetes. High consumption (> 2 servings per day) was positively associated with both 
LADA (OR 2.12, 95% CI 1.20-3.75) and type 2 diabetes (OR 3.31, 95% CI 2.07-5.31) 
compared to non-consumption. The associations remained also after inclusion of BMI in the 
models (LADA: OR 1.99, 95% CI 1.11-3.56, and type 2 diabetes OR: 2.39, 95% CI 1.39-4.09). 
In separate analysis by beverage type, OR per one additional daily serving of sugar-sweetened 
beverages was 1.18 (95% CI 1.00-1.39) for LADA and 1.21 (95% CI 1.05-1.41) for type 2 
diabetes after adjustment for BMI. The corresponding ORs for artificially sweetened beverage 
intake was 1.12 (95% CI 0.95-1.32) and 1.18 (95% CI 1.01-1.38) for LADA and type 2 
diabetes, respectively. 
5.5 PAPER IV: SWEETENED BEVERAGES, GENOTYPES, AND LADA 
In Paper IV, we show that HLA was strongly associated with LADA but not type 2 diabetes 
(Figure 5.3) and furthermore that the association with LADA pertained only to carriers of 
low/intermediate risk HLA genotypes but not to high risk carriers (Figure 5.4). TCF7L2 was 
associated with both LADA and type 2 diabetes, but did not seem to modify the association 
between sweetened beverages and neither LADA not type 2 diabetes. FTO was associated with 
type 2 diabetes but not with LADA, and FTO showed indications of being effect modifier in 
the association between sweetened beverage intake and type 2 diabetes. 
 
Figure 5.3. Age- and sex-adjusted OR with 95% CI of LADA and type 2 diabetes in relation to 
genotypes of HLA, TCF7L2 and FTO. 
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Figure 5.4. Multivariable adjusted OR of LADA and type 2 diabetes per 1 daily serving increment in 
intake of sweetened beverages, overall and by genotypes of HLA, TCF7L7 rs7903146, and FTO 
rs9939609. The models were adjusted for age, sex, education, physical activity, smoking, and alcohol 
intake. 
Sweetened beverage intake was positively associated with insulin resistance, measured as 
HOMA-IR, among individuals with type 2 diabetes both before (β=0.035, p < 0.001) and after 
(β=0.033, p < 0.05) adjustment for BMI. For LADA, similar tendencies were observed overall 
(β=0.051, p = 0.09, and β=0.043, p = 0.14), but stratification by HLA genotype indicated that 
the association was present only among carriers of low/intermediate risk HLA genotypes 
(β=0.162, p < 0.05, and β=0.122, p < 0.05). No associations were found with HOMA-B as an 
indicator of beta cell function. 
By means of causal mediation analysis, BMI was estimated to mediate 17% of the association 
with high sweetened beverage consumption for LADA and 56% for type 2 diabetes, while the 
estimated direct effect was of similar magnitude for both LADA and type 2 diabetes (Figure 
5.5). 
Figure 5.5. Estimated natural indirect effect, natural direct effect, and total effect of high sweetened 
beverage intake on the risk of LADA and type 2 diabetes. 
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6 DISCUSSION 
6.1 MAIN FINDINGS AND INTERPRETATIONS 
This doctoral thesis aimed to elucidate the risk of LADA in relation to consumption of fatty 
fish and sweetened beverages. The findings suggest that fatty fish is associated with reduced 
risk of LADA, possibly by beneficial effects of marine-originated n-3 PUFAs on progression 
from autoimmunity to diabetes onset. In contrast, sweetened beverage consumption was 
associated with an increased risk of LADA, with indications of mechanisms including 
detrimental effects on bodyweight and insulin resistance. Stratification by genotypes suggested 
that the positive association with sweetened beverages pertains only to individuals without 
HLA-conferred genetic susceptibility but that neither TCF7L2 nor FTO modified the 
association with LADA. The findings of this doctoral thesis clearly suggest that dietary factors 
may play a role in the development of LADA. These are the first studies investigating 
consumption of fish and sweetened beverages in relation to risk of LADA, thus confirmation 
and replication is warranted. 
6.1.1 Fish consumption 
The findings based on the ESTRID Study suggest that weekly fatty fish consumption is 
associated with a reduced risk of LADA. With data from EPIC-InterAct including both 
reported fish consumption and nutritional biomarkers, we found further support for a reduced 
risk of autoimmune diabetes in relation to the long-chain n-3 PUFA in fish. This is in line with 
previous reports in children [6, 7], although not with all [152, 153]. The mechanistic support 
for beneficial effects of EPA and DHA on autoimmunity and inflammation includes 
incorporation of these fatty acids into the cell membranes of immune cells, partly at the expense 
of arachidonic acid leading to a reduction in proinflammatory eicosanoid production [140]. 
Interestingly, there are potential links between n-3 PUFA and HLA-DR molecules, a type of 
cell surface receptors of antigen-presenting cells in the immune system encoded by the HLA 
genes. EPA and DHA have been shown to decrease HLA-DR concentration by down-
regulating gene expression of HLA-DR and costimulatory proteins in dendritic cells (type of 
immune cell) [203]. It may be hypothesized that lower levels of the HLA-DR receptors would 
lead to a less intense immune response and lower rate of beta cell destruction. Hence, EPA and 
DHA may potentially interact with HLA genotype on the risk of autoimmune diabetes. 
Potentially modifying effects of HLA and other genotypes in the association between n-3 
PUFA and LADA is thus an important topic for future studies. However, beneficial effects of 
vitamin D on development of autoimmune diabetes should not be ruled out as a potential 
explanation for our findings [118-120]. 
In EPIC-InterAct, we are assessing the risk of diabetes in relation to the interaction between 
baseline GADA positivity and dietary fish intake or plasma n-3 PUFA levels. The only 
previous study specifically addressing the potential role of n-3 PUFA on the progression from 
islet autoimmunity to diabetes onset found no association but was based on a limited number 
 32 
of children and all of them were at increased genetic risk [152]. Of note, plasma phospholipid 
EPA and DHA concentration has been positively associated with fasting C-peptide in youth 
newly diagnosed with type 1 diabetes, which may suggest a preserving effect on beta cells 
[204]. We are unable to disentangle whether our findings based on ESTRID may be related to 
development of autoimmunity or progression to clinical diabetes. Autoantibodies may be 
present several years prior to diabetes onset [205] but there is no information on antibody status 
prior to diagnosis for the cases in ESTRID. 
We did not observe an association between dietary fish intake and type 2 diabetes, which is in 
line with previously published data [149, 150]. Preparation method and exposure to 
contaminants such as PCBs and methyl mercury have been suggested to play a role in the 
relationship between fish intake and type 2 diabetes [150], but unfortunately we were not able 
to take these factors into account. It is however unclear to what extent these factors would 
differentially affect LADA and type 2 diabetes. 
6.1.2 Sweetened beverage consumption 
Consumption of sweetened beverages was found to be positively associated with both LADA 
and type 2 diabetes. This is in concordance with previous studies in type 2 diabetes [5] and two 
previous studies on type 1 diabetes in children [8, 9]. BMI has previously been suggested to 
mediate the association between sweetened beverage intake and type 2 diabetes [105]. We 
addressed this hypothesis by means of the causal mediation framework [198] and estimated 
that BMI mediates about half of the observed association between high intake of sweetened 
beverages and type 2 diabetes and 17% of the association with LADA. This fit with previous 
findings indicating that overweight is a less strong risk factor for LADA than for type 2 diabetes 
[28]. Furthermore, this speaks in favor of a direct effect of sweetened beverage consumption 
which may be of equal magnitude for LADA and type 2 diabetes. The overall positive 
associations with sweetened beverage intake, even after adjustment for BMI, found for 
HOMA-IR but not HOMA-B among type 2 diabetes patients and with similar tendencies for 
LADA provide support for a direct effect of sweetened beverages involving insulin resistance, 
which has been previously suggested. In addition, sweetened beverages may act through 
increased inflammation [164] and oxidative stress [165]. 
We observed a positive association with type 2 diabetes for both sugar-sweetened and 
artificially sweetened beverages, with similar indications for LADA although based on small 
numbers. Consumption of artificially sweetened beverages has previously been associated with 
type 2 diabetes [105, 171-173]. Although there are animal studies indicating a causal link 
between artificial sweeteners and impairments in glucose metabolism [169, 170], alternative 
explanations for the observed association between artificially sweetened beverages and 
diabetes risk need to be considered. It may be speculated that those consuming artificially 
sweetened beverages may have changed from previous consumption of sugar-sweetened 
beverages to prevent further weight gain [206]. In support hereof, we observed the highest BMI 
at present and at age 20 among high consumers of artificially sweetened beverages. 
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We also wanted to investigate whether genetic factors modify the association between 
sweetened beverages and LADA since it has been reported that the positive association 
between sugar-sweetened beverage intake and type 1 diabetes pertains only to children with 
high risk HLA genotypes [9]. Data from ESTRID and other studies [57, 58, 60, 61] show that 
HLA but also TCF7L2 are associated with increased risk of LADA, but our findings do not 
suggest that high risk genotype carriers of either genotype are particularly susceptible for 
adverse effects of sweetened beverage intake. Contrary, we found a positive association with 
sweetened beverage intake only among carriers of low/intermediate risk genotypes. This may 
be explained by differences in the pathophysiology of childhood type 1 diabetes and adults 
with LADA and may suggest that the relative contribution of environmental factors to risk of 
LADA is greater in individuals with lower genetic susceptibility. Interestingly, a rise in the 
frequency of low/moderate risk HLA genotypes in newly diagnosed type 1 diabetes patients 
have been observed over time, suggesting an increased importance of environmental factors in 
the development of disease [207]. 
6.2 METHODOLOGICAL CONSIDERATIONS 
6.2.1 Random errors 
The findings presented in Paper I were among the first analyses based on data from the ESTRID 
Study and included only 89 cases of LADA. Hence, these findings of an inverse association 
with fatty fish intake need to be interpreted with caution. A strength is that our findings based 
on EPIC-InterAct provides further support of an association between fatty fish intake and 
autoimmune diabetes. However, since GADA was measured at baseline and not at time of 
diagnosis in EPIC-InterAct, we could not address the risk of LADA per se, but rather the 
interplay between dietary fish/plasma n-3 PUFA levels and GADA positivity in relation to 
incidence of diabetes (either type 2 diabetes or LADA). The number of LADA patients in the 
ESTRID dataset is now considerably larger (n≈400) which means that we will have the 
opportunity to re-run the fatty fish analyses in ESTRID using four times as many cases. At the 
same time, further confirmation in independent data is essential. With regard to the sweetened 
beverages analyses, these have only been carried out in ESTRID so far, thus confirmation using 
a different population is of importance. 
6.2.2 Systematic errors 
6.2.2.1 Selection bias 
In ESTRID, controls were selected randomly and continuously from the same population in 
which the cases were generated. This method has high probability of providing a sample that 
is representative of the target population with regard to exposure prevalence [197]. Bias may 
be introduced if study participants differ from non-participants with regard to the exposure 
under study. The response rate among the ESTRID controls was 62% and in order to assess 
whether they are representative of the target population, we compared their consumption of 
fish and sweetened beverages to national intake level data. The agreement was high for mean 
sweetened beverage intake among both men (0.44 vs. 0.42 servings/day) and women (0.26 vs. 
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0.28 servings/day) [208]. The genetic controls (EIRA) had sweetened beverage consumption 
that was somewhat higher in males but lower in females compared to the national averages 
(0.47 and 0.21 servings/day, respectively). This does not seem to have influenced the results 
since the overall associations between sweetened beverages and LADA and type 2 diabetes 
were similar irrespective of whether ESTRID or EIRA (genetic) controls were used. National 
data on intake of dietary fish is not very detailed but 30% of adults consume fish at least twice 
weekly [209] and consumption increases with age [208]. The ESTIRD controls are largely in 
agreement with these numbers; 25% reported having fatty fish had more than twice weekly. 
Furthermore, the ESTRID controls have comparable education level as the general Swedish 
population (www.scb.se). 
Selection bias may also be discussed in relation to case recruitment. In the county of Scania, 
from where the vast majority of ESTRID cases is recruited, > 90% of all eligible patients were 
included in the ANDIS registry [23]. Almost all LADA patients (approx. 95%) are invited to 
ESTRID, and 83% of those choose to participate. For type 2 diabetes, the response rate is 
similar at 79%. In all, the impact of selection bias with regard to cases should be limited. 
For the EPIC-InterAct prospective case-cohort study, loss to follow-up may be an issue if it is 
differential with regard to level of dietary fish intake and probability of being detected as a 
case. A large number of sources were used for case ascertainment, including sources that do 
not rely on self-report, which would minimize loss to follow-up and increase the likelihood that 
any incomplete follow-up would be non-differential with regard to fish intake and plasma n-3 
PUFA level and would, if anything, lead to dilution of the observed associations. 
6.2.2.2 Misclassification of outcome 
In ESTRID, all diabetes cases were identified within the regional health care system and 
diagnosed according to national criteria. This means that undiagnosed cases will be missed and 
also that such cases may be found among the controls. Inclusion of controls with diabetes will 
make them more similar to the cases and consequently lead to dilution of the studied 
associations. In EPIC-InterAct, several sources of information, both self-report and objective 
sources, were used to identify and verify incident cases, which would minimize the number of 
unidentified cases and the number of false positive cases. Undiagnosed diabetes will however 
be present among the non-cases and potentially lead to bias if the incidence is related to dietary 
fish intake. 
GADA was the only antibody measured to indicate autoimmunity, and used to separate LADA 
from type 2 diabetes. Thus it is possible that individuals were positive for other antibodies (e.g. 
IAA, IA-2A, zinc transporter 8 antibody), which we did not have information on, and 
consequently some patients with autoimmune diabetes may have been missed. Importantly, 
GADA is present in 90% of adult patients with autoimmune diabetes [11, 205]. In ESTRID, 
the sensitivity of the GADA assay used was 84%, which means that some patients with LADA 
were erroneously classified as autoantibody negative. The specificity of 98% implies that type 
2 diabetes patients may be incorrectly classified as having LADA and this could contribute to 
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the similar associations with sweetened beverage intake seen for LADA and type 2 diabetes. 
Notably, the positive association with sweetened beverage intake was found also in analyses 
restricted to LADA with high GADA levels (i.e. above the median). Moreover, false positive 
LADA cases could not explain the differences in associations with fatty fish intake for LADA 
and type 2 diabetes found in Paper I. Importantly, we found that high risk HLA genotypes are 
associated with LADA but not type 2 diabetes, indicating that the GADA assay did identify 
two distinct patient groups. 
In the studies based on ESTRID, HOMA-IR was used to indicate degree of insulin resistance. 
Hence, we are not assessing insulin resistance per se. HOMA is widely used and has shown 
high validity as a proxy for insulin resistance in diabetes patients when compared to the “gold 
standard” tests of hyperinsulinemic-euglycemic and hyperglycemic clamps [210, 211]. 
6.2.2.3 Misclassification of exposure 
The FFQ used in ESTRID has been extensively validated against repeated 24-h recall 
interviews [182], weighed diet records [183], and adipose tissue n-3 PUFA content [184]. Yet, 
self-reported dietary intake is inherently afflicted with some degree of misreporting, often 
related to different characteristics such as bodyweight; in general, underreporting is more 
common among overweight individuals while underweight individuals are more likely to 
overreport [212]. Misreporting is especially problematic when dietary data are collected 
retrospectively, as in the ESTRID Study. Diet is essential in diabetes management and bias 
would be introduced if cases have changed their dietary intake after diagnosis and reported 
accordingly. To minimize bias, cases were specifically instructed to report diet as it was prior 
to diagnosis. In addition, we restricted the analyses of Paper I to cases who responded to the 
questionnaire within six months of diagnosis, and in Paper III, sensitivity analyses were 
conducted based on time since diagnosis. Notably, such bias would explain our findings only 
if cases would have decreased their fatty fish intake and increased their sweetened beverage 
consumption after diagnosis, which seems unlikely. Furthermore, it would not explain the 
observed differences between LADA and type 2 diabetes in relation to fatty fish consumption 
as we have no reason to believe that potential bias in the reporting would differ by diabetes 
type. Our findings for type 2 diabetes in relation to intakes of sweetened beverages and dietary 
fish concur with findings in prospective studies [5], which provide further support for the 
validity of our findings. Nevertheless, the potential issues with misreporting make the use of 
biomarkers as objective indicators of dietary intake appealing. In Paper II based on prospective 
data from EPIC-InterAct, exposure to n-3 PUFA was assessed by self-reported fish 
consumption but also by plasma phospholipid levels of n-3 PUFA. These findings were in line 
with the associations found in Paper I, supporting the hypothesis that n-3 PUFAs may have a 
role in the development of autoimmune diabetes. 
In EPIC-InterAct, dietary habits and plasma n-3 PUFA were assessed at baseline but 
participants may have changed their intakes of dietary fish during follow-up. Repeated 
measurements throughout follow-up would have been a way of minimizing bias due exposure 
misclassification, but no such information was available. Any misclassification of dietary 
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habits or n-3 PUFA levels could however be assumed to be non-differential with regard to 
diabetes status and hence lead to dilution of associations rather than spurious excess risks 
related to low fish/n-3 PUFA, but may distort potential dose-response relationships. Sensitivity 
and specificity of the GADA assay was high (85% and 99%, respectively). However, GADA 
status was assessed at baseline, which means that some of those classified as antibody negative 
may in fact have seroconverted during follow-up and this misclassification may lead to dilution 
and potential underestimation of the interaction between dietary fish/plasma n-3 PUFA and 
GADA positivity. 
BMI is an essential covariate closely linked to both dietary intake and diabetes risk, which is 
why it is of interest to consider its role as a potential mediator. BMI is based on self-reported 
data in ESTRID and in general, weight tends to be underreported and height tends to 
overreported [213]. However, correlation with BMI based on clinical measurements is high 
(r=0.92) for the cases in ESTRID. Still, BMI is a crude measure of body fat [214] and it is 
possible that we have underestimated the proportion of association mediated by BMI in the 
causal mediation analysis. Notably however, this may not speak against a common underlying 
mechanism for LADA and type 2 diabetes since the estimated direct effect of high sweetened 
beverage consumption was equal for both diabetes subtypes. 
6.2.2.4 Confounding 
A strength in the present studies was the detailed information on a large number of 
characteristics and lifestyle factors, such as education, smoking habits, physical activity, BMI, 
alcohol and other dietary components which could be included as covariates in the main 
statistical analyses. In Papers II and IV, it was not possible to adjust for family history, which 
is an important risk factor for both type 2 diabetes [215] and LADA [63]. However, the 
interactions between fish/n-3 PUFA and GADA on the risk of adult-onset diabetes reported in 
Paper II remained after additional adjustment for family history in sensitivity analysis. 
Furthermore, family history did not appreciably affect the association between sweetened 
beverage intake and LADA or type 2 diabetes in Paper III. We had detailed dietary data and 
the possibility to adjust for a large number of potential confounders including intakes of 
red/processed meat, sweet/salty snacks, coffee, whole grain, fruits, and vegetables. Still, we 
cannot exclude that our results are influenced by residual confounding, e.g. from inaccurately 
measured dietary confounders. 
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7 CONCLUSIONS 
This thesis aimed to explore the role of diet in the development of LADA, and more specifically 
the risk of LADA in relation to dietary fish and sweetened beverage consumption. The findings 
indicate that n-3 PUFAs, acquired predominantly through fatty fish intake, may decrease the 
risk of LADA. Ensuring adequate levels of long-chain n-3 PUFAs by regular consumption of 
fatty fish may be particularly important when autoantibodies are already present in order to 
delay the progression to diabetes in adults. Furthermore, high sweetened beverage consumption 
seems to increase the risk of LADA, possibly through mechanisms promoting insulin 
resistance. The increased risk may be limited to individuals with low HLA-conferred genetic 
susceptibility. 
These findings are well in line with the notion of LADA as a hybrid form of diabetes with risk 
factors related to both autoimmunity and insulin resistance. These were the first studies of the 
risk of LADA in relation to dietary fish and sweetened beverage consumption and it is 
important to confirm the associations in other populations. Still, these results add to the limited 
by growing body of evidence suggesting that lifestyle factors play a role in the development of 
LADA. Increased knowledge about modifiable lifestyle factors for LADA and their interaction 
with diabetes-related susceptibility genotypes may aid in the prevention and be a step towards 
reducing the burden of autoimmune diabetes. 
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8 FUTURE PERSPECTIVES 
The work of identifying lifestyle factors contributing to the development of LADA is still in 
its infancy and a lot remains to be explored. Diet has a large impact on health and disease and 
there is no shortage in factors hypothesized to have role in processes related to autoimmunity 
and insulin resistance. 
There are currently no prospective studies of LADA with dietary intake data available. Such 
studies would add valuable information on the role of diet in the development of LADA. The 
use of biomarkers and repeated measurements of exposures and autoantibody status would 
enable even more detailed analyses. 
The potential interaction between genetic and dietary factors is an interesting area that needs 
to be further explored, especially in times when increased attention is given to precision 
medicine. 
Exploring the roles of individual foods and nutrients is of importance for increased 
understanding of possible routes of action, but diet is likely to be a complex interplay and it is 
of equal importance to study dietary patterns to account for synergistic effects. 
The role of diet in the prognosis of LADA including potential diet–drug interactions is another 
unexplored area. 
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